Global contract development and manufacturing organizations (CDMOs) BioCina and NovaCina have announced a strategic merger that will create a strong brand in the biopharmaceutical and small molecule contract manufacturing space. The combined company, which will retain the BioCina name, will be fully integrated to provide the market with a seamless, comprehensive offering, from cell line and process development through clinical and commercial drug substance to sterile drug fill. With this new comprehensive service offering, BioCina is able to meet the ever-growing demand for high-quality, integrated production solutions for customers in the US, Europe, Asia, Australia and beyond.
The merger will bring together BioCina’s world-class process development and manufacturing expertise for the microbial, plasmid DNA and mRNA modalities at its Adelaide, South Australia site with NovaCina’s state-of-the-art sterile filling facility in Perth, Western Australia More than 600 biological and small molecule products have already been manufactured. Customers are supported by highly qualified technical specialists with an average length of service of more than ten years. The synergistic union provides a streamlined, customer-centric experience managed by a single entity. Flexible, phase-appropriate solutions characterized by exceptional quality and industry-leading delivery reliability (on-time and in-full (OTIF)) are now the cornerstones of BioCina. BioCina has a world-class regulatory track record, including approvals from the US FDA, EMA, TGA and Health Canada. Additionally, drug developers will continue to benefit from Australia’s outstanding tax incentive of up to 48.5% for CDMO programs operating in Australia.
Mark W. Womack, who has successfully led BioCina’s explosive growth and development over the past two years, will continue as Managing Director. Womack has long been known for his visionary leadership, creating a truly customer-focused culture and having delivered exceptionally reliable operational performance across numerous successful organizations. Previously, Womack was CEO of KBI Biopharma and Stelis Biopharma, as well as managing director of AGC Biologics, where he was instrumental in the company’s expansion.
“The combination of these two companies is nothing short of ideal and we have great confidence in what they will achieve together, especially with Mark at the helm. The industry is changing rapidly and becoming increasingly complex. New drug developers and experienced biopharma companies are looking for a trusted CDMO partner to work hand-in-hand with them to bring their products to market efficiently and with streamlined regulatory approval. Each of these companies is excellent in its own right. Together they will advance the industry’s capabilities and standards and deliver an unparalleled offering,” said Masood Tayebi, co-founder and managing director of Bridgewest Group, the parent company of both companies.
“I am thrilled to lead this dynamic new organization. This merger solidifies our position in the industry as the most trusted and customer-focused end-to-end CDMO for the global biopharmaceutical and small molecule industries,” said Mark W. Womack, Managing Director of BioCina.
Information about New BioCina
BioCina is a global contract development and manufacturing organization (CDMO) that offers its customers unparalleled quality, compliance with the highest regulatory standards and industry-leading on-time and complete delivery, setting new industry standards for quality and reliability sets. With extensive expertise in small molecules, microbes, pDNA and mRNA modalities, BioCina’s broad service offering includes cell line development, process development, analytical and formulation development, and clinical and commercial cGMP manufacturing.
BioCina operates two state-of-the-art facilities in Adelaide, South Australia and Perth, Western Australia. The facilities have a long history of developing and manufacturing clinical and commercial drug compounds and products, supported by highly experienced subject matter experts with an average tenure of more than ten years.
BioCina has first-class quality that meets the highest international standards. The facilities have successfully passed regulatory inspections by the US FDA, EMA and Health Canada and are licensed by the Australian TGA for cGMP manufacturing of bulk and sterile drug products. BioCina has a proven track record of producing high quality medicines distributed in 98 countries across North America, South America, Europe, Asia and Africa.
BioCina is proud to serve customers from all major markets in the global industry. Since BioCina is not a drug developer, its focus is exclusively on supporting its customers’ products.
Australia offers one of the world’s most attractive tax breaks (up to 48.5% cash rebate), making it an optimal location for drug developers looking to invest in scaling and manufacturing their products.
As one of the fastest growing companies in the biopharmaceutical industry across Australia, BioCina has been awarded South Australia’s 2024 Emerging Business of the Year Award.
For more information, see https://biocina.com.